3,141 research outputs found
Radial shortening for the treatment of Kienböck's disease
Twelve patients with Kienbock's disease were treated by radial shortening. Eight
patients were in stage II and four in stage III. After an average of 5 years,
relief of pain was satisfactory in 10 patients; 8 were in stage II before
operation and 2 in stage III. Two patients were dissatisfied because they had
persistent pain; both were in stage III before surgery. The range of motion
improved moderately. Nonunion at the site of radial osteotomy did not occur.
Radiographs at follow up showed consolidation and healing of the lunate in 2
patients, nonprogression of the disease in 9 and increase of the carpal collapse
in 1. The procedure helps to prevent further collapse of the lunate especially in
stage II and in some patients in stage III
Use of brachytherapy in children with cancer: the search for an uncomplicated cure
Brachytherapy is a sophisticated radiation method in which radioisotopes are
placed inside or at a short distance from the tumour. The volume of tissue that
receives the prescribed dose of radiotherapy is therefore fairly small compared
with that used in standard radiotherapy techniques. In paediatric oncology, this
method of radiation delivery can have a favourable effect on several undesirable
long-term side-effects that sometimes develop in children who receive
radiotherapy, such as growth retardation and development of second primary
tumours. Here, we describe the rationale for use of brachytherapy in children
with cancer, the methods of the different brachytherapy techniques available, and
the results obtained with several brachytherapy regimens in expert institutions
throughout the world
A case of capecitabine-induced coronary microspasm in a patient with rectal cancer
5-Fluorouracil (5-FU) is the most frequently used chemotherapy agent concomitant with radiotherapy in the management of patients with rectal cancer. Capecitabine is an oral fluoropyrimidine that mimics the pharmaconkinetics of infusional 5-FU. This new drug is replacing 5-FU as a part of the combined-modality treatment of a number of gastrointestinal cancers. While cardiac events associated with the use of 5-FU are a well known side effect, capecitabine-induced cardiotoxicity has been only rarely reported. Here, we reviewed the case of a patient with rectal cancer who had a capecitabine-induced coronary vasospasm. The most prominent mutation of the dihydropyrimidine dehydrogenase gene was also analyzed
Feasibility report of conservative surgery, perioperative high-dose-rate brachytherapy (PHDRB), and low-to-moderate dose external beam radiation therapy (EBRT) in pediatric sarcomas
This study was undertaken to determine the feasibility of perioperative
high-dose-rate brachytherapy (PHDRB) as an accelerated boost in patients with
pediatric sarcomas. METHODS AND MATERIALS: Five pediatric patients (ages 7-16)
with soft tissue sarcomas (STS) or soft tissue recurrences of previously treated
osteosarcomas were treated with surgical resection and PHDRB (16-24 Gy) for R0-R1
resections. Patients with STS and osteosarcomas received 27 Gy and 45 Gy of EBRT
postoperatively. RESULTS: After a median follow-up of 27 months (range, 12-50)
all the patients remain locally controlled. Only 1 patient developed regrowth of
pulmonary metastases and died of distant disease at 16 months. CONCLUSIONS: The
use of PHDRB is safe in the short-term in this pediatric population. Only 1
patient suffered a partial wound dehiscence that may not be entirely related to
PHDRB. Patients with recurrent osteosarcomas can be treated in a fashion similar
to their adult soft tissue counterparts and avoid limb amputation. Younger
patients with STS may achieve local control and prevent growth retardation with a
combination of PHDRB and moderate doses of EBR
Tratamiento radioterápico del cáncer mama: estándares y nuevas tendencias. Irradiación parcial acelerada de la mama
Radiotherapy as a part of the breast cancer treatment has evolved in the last decades. Post-mastectomy radiotherapy produces a substantial reduction in the risk of local recurrence as well as a moderate, but definitive reduction in long-term breast cancer mortality in women at high risk of locoregional failure. Whole-breast irradiation, as part of breast-conservation therapy, has well-established results with good cosmesis, and low toxicity. Results from the BCT trials suggest that the risk for ipsilateral breast cancer recurrence resides within close proximity to the original tumor site. This has led investigators to consider the role of an accelerated and more tumor bed-focused course of radiotherapy. Accelerated partial-breast irradiation (APBI) is a collection of radiotherapy techniques that deliver higher daily doses of radiation to the surgical cavity with margin over a shorter time than whole breast irradiation (from 6-6.5 weeks to 1 week). Early results of this approach have demonstrated excellent local control, minimal acute toxicity, and are more convenient for the patient. Phase III randomized clinical trials are currently underway to assess local control, acute and chronic toxicities. APBI extend the choise of breast conservatio
Comportamiento mecánico en función de la temperatura de aleaciones wolframio-vanadio.
En esta investigación se evalúa el comportamiento mecánico del wolframio puro y de dos de sus aleaciones con contenidos de 2% y 4% de vanadio, fabricadas mediante prensado isostático en caliente (HIP). La caracterización mecánica se ha realizado mediante ensayos de flexión en tres puntos en atmósfera oxidante a distintas temperaturas comprendidas entre temperatura ambiente y 1000 ºC. Adicionalmente, se han realizado ensayos en inmersión en nitrógeno líquido para los de -197 ºC. Estos últimos valores pueden servir para una determinación más precisa de la temperatura la transición dúctil-frágil en éstos materiales, y de su posible comportamiento plástico o frágil a temperatura ambiente. Mediante estos ensayos ha sido posible obtener la tenacidad de fractura, la resistencia mecánica, el límite elástico y el módulo de elasticidad en función de la temperatura. Así mismo, se ha determinado la densidad y la dureza Vickers para dos cargas distintas, lo que permitido determinar la influencia de este parámetro en la medida realizada. Adicionalmente, se han examinado mediante microscopia electrónica de barrido las superficies de fractura. De esta forma ha sido posible determinar el modo de rotura y analizar la relación de las propiedades mecánicas macroscópicas con los micromecanismos de fallo involucrados
Multiple cycles of dose-intensive chemotherapy with repeated stem cell support as induction treatment in metastatic breast cancer: a feasibility study
The purpose of this trial was to study feasibility and tolerance of a dose-intensive multicyclic alternating induction chemotherapy with repeated stem cell support in a series of 43 metastatic breast cancer patients. Anthracycline-naive patients (n = 21) received cyclophosphamide 2.5 g/m2 plus doxorubicin 80 mg/m2 alternating every 14 days with paclitaxel 200-350 mg/m2 plus cisplatin 120 mg/m2. Patients who had previously received anthracyclines (n = 22) received cisplatin 120 mg/m2 plus etoposide 600 mg/m2 alternating with paclitaxel 200-350 mg/m2 plus ifosfamide 8 g/m2. Peripheral blood stem cells were infused after every course except the first, with a median CD34+ dose of 2.1 ´ 106/kg per cycle. Positive selection of CD34+ cells was performed in good mobilizers. The median number of cycles administered was six (4-8), and the time interval between them was 17 days. Median summation dose intensities (SDI) actually administered for the CA-TP and PE-TI protocol were 4.95 and 4.69, respectively (87% of scheduled SDI). There were 15 complete (35%) and 21 partial responses (49%), for an overall response rate of 84% (95% CI, 73%-95%). Infection or neutropenic fever occurred in 50% of the cycles. There was one treatment-related death. After a median follow-up of 26 months, the median event-free-survival was 12 months (95% CI: 10-14) and overall survival was 31 months. These high dose-intensity induction treatments seem to be feasible with sequential stem cell support
Valor de la PET en la recurrencia del cáncer de próstata con PSA < 5 ng/ml
We intend to evaluate the usefulness of PET scans in diagnosing recurrent prostate cancer after a curative attempt using radical treatment.
MATERIAL AND METHODS:
92 consecutive prostate cancer patients in biochemical progression following radical surgery (63) or radiation treatment (29) were studied with positron emission tomography (PET). In all cases two scans were performed in the same day (11C-choline and 18F-FDG). PET efficacy was evaluated both globally (by employing the results achieved with both 11C-choline and 18F-FDG) and using both radiotracers independently to detect recurrence in patients with biochemical progression. For this purpose, we used comparison of means for k-independent samples, 2 x 2 and 2 x X contingency tables and ROC curves.
RESULTS:
1. Global PET: there is evidence of PET alteration regarding the PSA level (P=.003): the clinical stage (P=.01). There are no statistically significant PET alterations regarding the affected biopsy (uni or bilateral), surgical margins, pathological stage and time to progression. ROC curve PET-PSA is statistically significant (P< .0001) permitting calculation of different cut-off points, with a specificity of 91% (highest) for a PSA of 4.3 ng/ml. 2. PET 18FDG: the area under the ROC curve is statistically significant (P< .0001) with a specificity of 91% for a PSA of 6.51 ng/ml. 3. PET 11choline: the area under the ROC curve is statistically significant (P< .0001) with a specificity of 91% for a PSA of 5.15 ng/ml.
CONCLUSIONS:
PET is a useful tool for diagnosing prostate cancer recurrence after a curative attempt using radical treatment
- …